ChengDu ShengNuo Biotec Co.,Ltd.

Shanghai Stock Exchange 688117.SS

ChengDu ShengNuo Biotec Co.,Ltd. Current Liabilities for the year ending December 31, 2023: USD 33.98 M

ChengDu ShengNuo Biotec Co.,Ltd. Current Liabilities is USD 33.98 M for the year ending December 31, 2023, a 4.23% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

ChengDu ShengNuo Biotec Co.,Ltd. Current Liabilities for the year ending December 31, 2022 was USD 32.60 M, a 27.52% change year over year.
ChengDu ShengNuo Biotec Co.,Ltd. Current Liabilities for the year ending December 31, 2021 was USD 25.57 M, a 15.08% change year over year.
ChengDu ShengNuo Biotec Co.,Ltd. Current Liabilities for the year ending December 31, 2020 was USD 22.22 M, a 17.86% change year over year.
ChengDu ShengNuo Biotec Co.,Ltd. Current Liabilities for the year ending December 31, 2019 was USD 18.85 M, a -5.03% change year over year.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

Shanghai Stock Exchange: 688117.SS

ChengDu ShengNuo Biotec Co.,Ltd.

CEO	Mr. Yongjun Wen
IPO Date	June 3, 2021
Location	China
Headquarters	258 Industrial Avenue Section
Employees	1,128
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company produces polypeptide APIs, tablets of solid preparation, bottles of freeze-dried powder injections, small-volume injections, pre-filled injections, and card type injections. ChengDu ShengNuo Biotec Co.,Ltd. was founded in 2001 and is based in Chengdu, China.

Key trends

Past 5 years